Abstract:Objective: The COVID-19 pandemic had a huge impact on access to healthcare and on the presence of follow-up visits in ambulatory care. This study evaluated the influence of the COVID-19 pandemic on blood pressure (BP) control and phenotypes as assessed by office and 24-hour ambulatory BP monitoring (ABPM). Design and method: Clinical and BP data were collected from 33 centers including Excellence Centers of the European Society of Hypertension. Two groups of patients with treated hypertension were compared. Group1 (pandemic): including participants who had ABPM twice - at visit 2 during the COVID-19 pandemic and visit 1 performed 9-15 months prior to visit 2. Group2 (pre-pandemic): had ABPM in two visits, performed before the pandemic within 9-15 months interval. In the current analysis we determined BP phenotypes among all patients. The following phenotypes were distinguished: masked uncontrolled hypertension (MUCH), white coat uncontrolled hypertension (WUCH), sustained controlled hypertension (SCH) and sustained uncontrolled hypertension (SUCH), according to ESH 2023 Guidelines. We analyzed whether these phenotypes changed between visits. Results: Of overall 1620 patients included in the study, we excluded those with missing ABPM or clinical data precluding to define BP phenotypes. Patients with uncontrolled hypertension on both visits and patients switching between MUCH and WUCH were also excluded. Finally, data of 983 patients, 423 (43%) in the pandemic group and 560 (57%) in the pre-pandemic group were analyzed. At baseline (visit 1), BP phenotypes prevalence did not differ between groups. In the pandemic group, the prevalence of SUCH increased during follow up (9% vs 20.8%, p<0.001), while the prevalence of SCH remained unchanged between visits (43.7% vs 46.3%, p=0.45). In contrast, in the pre-pandemic group, the prevalence of the SCH increased during follow-up (41.3% vs 55%, p <0.001). On visit 2 in the pandemic group, the prevalence of SCH was lower than in the pre-pandemic group (46.3% vs 55%, p=0.007). In multivariable adjusted analysis, the only significant factor influencing the negative changes of BP phenotypes was the COVID-19 pandemic period. Conclusions: These results indicate a negative impact of the COVID-19 pandemic on BP control assessed by BP phenotypes.

Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension

THE IMPACT OF COVID-19 PANDEMIC ON BLOOD PRESSURE CONTROL IN PATIENTS WITH TREATED HYPERTENSION. RESULTS OF EUROPEAN SOCIETY OF HYPERTENSION STUDY (ESH ABPM COVID-19 STUDY)

The impact of the COVID-19 Pandemic on hypertension phenotypes (ESH ABPM COVID-19 study)

Decline of Admission for Acute Coronary Syndromes and Acute Cardiovascular Conditions During COVID-19 Pandemic in Veneto Region.

THE IMPACT OF THE COVID-19 PANDEMIC ON OFFICE AND 24-HOUR BLOOD PRESSURE PHENOTYPES (ESH ABPM COVID-19 STUDY)

COVID-19 pandemic impact on hypertension management in North East London: an observational cohort study using electronic health records

Hypertension management and outcomes during the covid-19 pandemic: diagnosis, blood pressure telemonitoring use and mortality

Changes in Blood Pressure Outcomes Among Hypertensive Individuals During the COVID-19 Pandemic: A Time Series Analysis in Three US Healthcare Organizations

BLOOD PRESSURE CONTROL IN TERTIARY-CARE HYPERTENSIVE PATIENTS DURING COVID-19 PANDEMIC

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Impact of the COVID-19 pandemic on hospital admission rates for arterial hypertension and coronary heart disease: a German database study

Abstract P168: Hypertensive Emergency And Covid-19 Outcomes 2020

Impact of hypertension on mortality in patients with ST-elevation myocardial infarction undergoing primary angioplasty: insights from the international multicenter ISACS-STEMI registry

Changes in blood pressure measurement prevalence among United States adults with hypertension before and during the COVID-19 pandemic

Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic

Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020)

Impact of COVID-19 on the management of hypertension: a perspective on disease severity, service use patterns and expenditures from Ghana's health insurance claims data

Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension

National Cross-Sectional Epidemiological Analysis of the Impact of Pandemic COVID-19 on Vascular Procedures in Public Health System: 521,069 Procedures Over 4 Years

Hypertension Control During the Coronavirus Disease 2019 Pandemic

Clinical outcomes for patients with cardiovascular diseases before, during, and after the COVID19 pandemic. A pooled analysis of 600.000 patients.